MITSUI-CHEMICALS
5.10.2022 10:01:36 CEST | Business Wire | Press release
Mitsui Chemicals, Inc. (Tokyo: 4183; President & CEO: HASHIMOTO Osamu) and Mitsui Chemicals Europe GmbH (Düsseldorf, Germany; President: HIRAIWA Takeshi) will exhibit at K2022 – the World’s No.1 Trade Fair for Plastics and Rubber as the Mitsui Chemicals Group.
The event is scheduled to be held from October 19–26, 2022 in Düsseldorf, Germany.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221005005348/en/
Mitsui Chemicals Group booth (Graphic: Business Wire)
At the trade fair, under the slogan “Feel Good Chemistry for a sustainable world”, the Mitsui Chemicals Group will present innovative materials and solutions that contribute to the circular economy, and a carbon neutral and sustainable society. In addition, technical presentations will be held on October 20th and 24th.
Come and meet us at our booth at K 2022 (hall 7a, booth D18).
- Overview of Mitsui Chemicals Group‘s Exhibition
Exhibition period: |
October 19 (Wed) – October 26 (Wed), 2022 |
Venue: |
Düsseldorf Fairgrounds / Düsseldorf, Germany |
Booth location: |
7a / D18 |
- Exhibition items of Materials and information
Products/Solutions |
Theme |
Arlen™ |
A modified polyamide 6T, heat & hydrolysis resistance for metal replacements and EV components |
Aurum™ |
(TPI), a super engineering plastic for high performance applications at extreme temperatures |
Arcus™ |
Solution service for polymer robot parts including material design/selection and production. |
Exfola™ |
Sealant film for packaging with good oil and water repellency |
Econykol™ |
Biomass based polyols for polyurethanes that contributes to reduce greenhouse gas emissions |
Recycle solutions
|
RePLAYERTM – Renewable plastic layer system - Mono-material packaging solutions Paper packaging solutions |
TAFNEX™ |
Composite material based on polypropylene and carbon fibre for structural and aesthetic applications |
TPXTM |
Polymethylpentene (PMP), a polyolefin based polymer with extremely low density, high melting point, releasability and steam resistance for autoclavable medical and laboratory equipment |
Advanced Module Concept |
Advanced module concept for back-door and slide-door |
Eco-bench |
MMP (Mold Master Plate) - sandwich molding (Recycling) |
- Technical presentations
- October 20, 11:00 o’clock
Theme: "AURUMTM thermoplastic polyimide (TPI)
An innovative solution for the demanding application requirements by maintaining excellent mechanical performance at extreme temperatures"
Presenter: Samer Ziadeh
Technical Expert, Product Support Team, R&D Division
- October 24, 14:00 o’clock
Theme: "Decorative design options with thermoplastic composites based on carbon fiber and polypropylene"
Presenter: Dr. Christos Karatzias
Senior Manager, New Business Development Team, R&D Division
Please visit our dedicated website for more details.
https://eu.mitsuichemicals.com/special/k2022/
About Mitsui Chemicals (Tokyo: 4183, ISIN: JP3888300005)
Mitsui Chemicals’ roots can be traced back to 1912 when it began producing raw material for chemical fertilizers from coal gas byproducts, the first company in Japan to do so. This undertaking significantly contributed to increasing agricultural productivity, a major social issue at the time. Later, the company evolved its technology from coal chemicals to gas chemicals, and in 1958 it built Japan’s first petrochemical complex and so provided impetus to Japan’s industry. Today, the company boasts many world-class products with sales standing at over 1,600 billion yen and with over 160 companies in 30 countries. Its business portfolio includes Life & Healthcare Solutions, Mobility Solutions, ICT Solutions, Basic & Green Materials.
Mitsui Chemicals will continue to contribute to solving social challenges with its state-of-the-art technology and by "Creating New Customer Value through Innovation".
More information can be found at https://www.mitsuichem.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221005005348/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Mobix Labs Signs Definitive Agreement to Acquire Vision Aerial, Accelerating Global Drone Platform for National Security and Aerial Intelligence24.7.2026 13:00:00 CEST | Press release
Transaction accelerates Mobix Labs’ global aerial intelligence strategy and National Security Matters Initiative Mobix Labs, Inc. (Nasdaq: MOBX) today announced that it has signed a definitive agreement to acquire Vision Aerial, Inc., a U.S.-based designer and manufacturer of American-built, National Defense Authorization Act (NDAA)-compliant unmanned aerial systems. The definitive agreement moves the transaction beyond the previously announced letter of intent and represents a major step toward closing an acquisition that would expand Mobix Labs into one of the world’s most important technology growth markets: secure drones, autonomous aerial systems and aerial intelligence for national security, critical infrastructure, energy, public safety, industrial inspection and government operations. Vision Aerial’s customers and end-users include the U.S. Air Force, U.S. Navy, government agencies, energy and utility operators, research institutions and other organizations requiring performanc
Enhertu® Plus Pertuzumab Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with HER2 Positive Metastatic Breast Cancer24.7.2026 13:00:00 CEST | Press release
Recommendation based on DESTINY-Breast09 phase 3 trial results that showed Enhertu plus pertuzumab reduced the risk of disease progression or death by 44% versus THP with a median progression-free survival exceeding three years If approved, Daiichi Sankyo and AstraZeneca’s Enhertu plus pertuzumab would become first new treatment in the EU in more than a decade for first-line HER2 positive metastatic breast cancer Enhertu® (trastuzumab deruxtecan) in combination with pertuzumab has been recommended for approval in the European Union (EU) for the first-line treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+ or in-situ hybridization [ISH]+) breast cancer. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP)
SLB Announces Second-Quarter 2026 Results24.7.2026 12:50:00 CEST | Press release
Revenue of $8.97 billion increased 3% sequentially and 5% year on year GAAP EPS of $0.52 increased 4% sequentially and decreased 30% year on year EPS, excluding charges and credits, of $0.55 increased 6% sequentially and decreased 26% year on year Net income attributable to SLB of $786 million increased 5% sequentially and decreased 22% year on year Adjusted EBITDA of $1.90 billion increased 7% sequentially and decreased 7% year on year Cash flow from operations was $1.36 billion and free cash flow was $716 million Board approved quarterly cash dividend of $0.295 per share SLB (NYSE: SLB) today announced results for the second-quarter 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260722694386/en/ The exterior of the SLB headquarters in Houston, Texas.Second-Quarter Results(Stated in millions, except per share amounts)Three Months EndedChangeJun. 30, 2026Mar. 31, 2026Jun. 30, 2025SequentialYear-on-yearRevenue $8,972 $8
NIQ Expands GenAI Capabilities Across gfknewron, Turning Trusted Intelligence into Decisions Faster24.7.2026 12:30:00 CEST | Press release
New capabilities help businesses uncover trends faster, simplify complex analysis, and accelerate confident decision-making NIQ (NYSE: NIQ), a leader in consumer intelligence, today announced the expansion of AI-powered Smart Insights across its gfknewron® platform. By bringing together markets and categories into a single view, gfknewron enables businesses to transform complex market, consumer and supply chain data into clear, actionable intelligence quickly. The latest enhancements help users identify trends, opportunities and performance drivers more quickly, reducing the time required to analyze large datasets and accelerating confident decision-making across teams. As brands and retailers face growing pressure to respond quickly to changing consumer behavior and market dynamics, the ability to unlock meaningful insights from increasingly rich datasets has become a significant competitive advantage. As AI is only as effective as the intelligence behind it, Smart Insights helps busi
Thales to Strengthen Romania’s Airspace Protection With Twelve Ground Master 200 MM/A Radars24.7.2026 10:05:00 CEST | Press release
The Romanian General Directorate for Armaments and the French Direction Générale de l’Armement (DGA – the French defence procurement agency) have signed an agreement to supply twelve Thales GM200 Multi-Mission All-in-one (GM200 MM/A) radars to protect the Romanian airspace. This government-to-government agreement underlines the high level of partnership between France and Romania, within the framework of the European Union’s SAFE funding programme, in order to bolster Europe’s defence capabilities. The GM200 MM/A is part of Thales’ proven Ground Master radar family, which has already been deployed in over 40 countries, including now in Romania. In a context of growing collaboration between European nations to bolster collective security, the Romanian General Directorate for Armaments has just signed a landmark agreement with France’s Direction Générale de l’Armement (DGA) to acquire twelve Thales Ground Master 200 Multi-Mission All-in-one (GM200 MM/A) radars. This government-to-governm
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom